2Opelz G. Influence of treatment with cyclosporine, azathioprinc and steroids on chronic allogeaft failure. The collaborative transplant study[J]. Kidney Int, 1995, 52:89.
3Nicholls A J.Opportunties for therapeutic drug monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection[J].Clin Biochem, 1998, 31(5):329.
4Mcgara MJ, Lee CH, Weinberg GA, et al. IMP dehydrogenase from pneumocystis carini as a potential drug target [J]. Antimicrob Agents Chemother, 1997, 41: 40.
5Dumont FJ, Staruch MJ, Koprak SL, et al. The immunosuppressive macrolides FK506 and rapamycin act as reciprocal antagonists in murine T cells[J].J Immunol,1990, 144: 251.
6Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus(FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 kidney transplant study group[ see comments] [J ]. Transplantation, 1997, 63: 977.
7Przepiorka D, Nash RA, Wingard J R, et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation[J]. Biol Blood Marrow Transplant, 1999, 5(2) :94.
8Hedayat S, Kershner RP, Su G.Relationship of whole blood Fk506 concentrations to rejection and toxicity in liver and kidney transplants[J].J Biolpharm Stat, 1996,6(4):411.
9Kahan, BD, Julian BA, Pescovitc MD, et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primany renal allografts:A phase Ⅱ trial[J].Trasplantation, 1999, 68(10): 1 526.
